Cosciens Biopharma Inc (CSCI)

Apr 01, 2025

COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks

Apr 01, 2025

Apr 01, 2025

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard

Apr 01, 2025

Apr 01, 2025

Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan

Apr 01, 2025

Mar 21, 2025

Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey

Mar 21, 2025

Mar 21, 2025

COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

Thursday’s 10 Worst-Performing Stocks - Insider Monkey

Mar 21, 2025

Mar 20, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN

Mar 20, 2025

Mar 20, 2025

Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener

Mar 20, 2025

Mar 20, 2025

Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - Marketscreener.com

Mar 20, 2025

Mar 20, 2025

COSCIENS Biopharma flags potential reporting delay - Investing.com

Mar 20, 2025

Mar 19, 2025

COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks

Mar 19, 2025

Mar 19, 2025

Material Control Issues Force COSCIENS to Delay Critical Financial Reports - StockTitan

Mar 19, 2025

Mar 19, 2025

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents - The Manila Times

Mar 19, 2025

Mar 19, 2025

COSCIENS Biopharma Inc. Announces Potential Delay in Annual Financial Filing Due to Audit Complexities - Nasdaq

Mar 19, 2025

Mar 19, 2025

Cosciens Biopharma announces possible delay in filing 2024-end documents - TipRanks

Mar 19, 2025

Mar 19, 2025

Material Control Issues Force COSCIENS to Delay Critical Financial Filings Until Q2 - StockTitan

Mar 19, 2025

Mar 18, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last We - Asianet Newsable

Mar 18, 2025

Mar 16, 2025

1 Growth Stock Down 45% to Buy Right Now, According to Wall Street - The Globe and Mail

Mar 16, 2025

Mar 13, 2025

COSCIENS advances to Phase 2a study for inflammation treatment By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

CSCI stock touches 52-week low at $2.28 amid market challenges - Investing.com

Mar 13, 2025

Mar 13, 2025

CSCI stock touches 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

COSCIENS Biopharma Advances Avenanthramides to Phase 2a Trial - TipRanks

Mar 13, 2025

Mar 13, 2025

COSCIENS advances to Phase 2a study for inflammation treatment - Investing.com India

Mar 13, 2025

Mar 13, 2025

Cosciens Biopharma to Start Phase 2a of Inflammation Drug Candidate -March 13, 2025 at 08:21 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - The Manila Times

Mar 13, 2025

Mar 13, 2025

COSCIENS Biopharma Initiates Phase 2a Clinical Efficacy Study for Avenanthramides Product Following Successful Phase 1 Safety Results - Nasdaq

Mar 13, 2025

Mar 13, 2025

Cosciens Biopharma announces initiation of Phase 2a study for avenanthramides - TipRanks

Mar 13, 2025

Feb 18, 2025

Septerna pulls lead hypoparathyroidism drug on bilirubin levels - BioWorld Online

Feb 18, 2025

Dec 23, 2024

COSCIENS Biopharma halts investment in macimorelin; CMO to depart - Seeking Alpha

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Focuses on Natural Product Growth - TipRanks

Dec 23, 2024

Dec 23, 2024

Cosciens Biopharma provides update, reiterates pipeline prioritization - TipRanks

Dec 23, 2024

Dec 23, 2024

Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization - GlobeNewswire

Dec 23, 2024

Dec 23, 2024

COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline - StockTitan

Dec 23, 2024

Dec 20, 2024

CSCI stock touches 52-week low at $2.61 amid market challenges - Investing.com Australia

Dec 20, 2024

Dec 20, 2024

CSCI stock touches 52-week low at $2.61 amid market challenges By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 16, 2024

COSCIENS Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 16, 2024

Dec 05, 2024

This Biopharma Stock Could Be 2025’s Biggest Comeback Story - Wealth Awesome

Dec 05, 2024

Dec 02, 2024

Aeterna Zentaris : to Present at Upcoming Biotech Showcase Conference in San Francisco - Marketscreener.com

Dec 02, 2024

Nov 22, 2024

CSCI stock touches 52-week low at $2.8 amid market challenges - Investing.com Canada

Nov 22, 2024

Nov 22, 2024

CSCI stock touches 52-week low at $2.8 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 15, 2024

Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn

Nov 15, 2024

Nov 15, 2024

COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

COSCIENS Biopharma: Q3 Earnings Snapshot - The Pioneer

Nov 13, 2024